{"id":"deucrictibant-high-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Deucrictibant works by blocking the action of bradykinin at its receptor, which is involved in blood pressure regulation. This leads to vasodilation and a decrease in blood pressure. Deucrictibant is being investigated for its potential to treat hypertension.","oneSentence":"Deucrictibant is a bradykinin receptor 2 antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:31:58.550Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT05396105","phase":"PHASE2, PHASE3","title":"Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","status":"ENROLLING_BY_INVITATION","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-12-28","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":150},{"nctId":"NCT04618211","phase":"PHASE2","title":"Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","status":"COMPLETED","sponsor":"Pharvaris Netherlands B.V.","startDate":"2021-02-03","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":74},{"nctId":"NCT05047185","phase":"PHASE2","title":"Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II","status":"COMPLETED","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-04-19","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Deucrictibant high dose","genericName":"Deucrictibant high dose","companyName":"Pharvaris Netherlands B.V.","companyId":"pharvaris-netherlands-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deucrictibant is a bradykinin receptor 2 antagonist. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}